Open access
Open access
Powered by Google Translator Translator

All Posts

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

19 Oct, 2021 | 10:14h | UTC

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine

Related:

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

 

Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days compared to placebo”.

19 Oct, 2021 | 10:13h | UTC

Colchicine for the treatment of COVID‐19 – Cochrane Library

Related:

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

 

Commentary on Twitter

 

China’s COVID vaccines have been crucial — now immunity is waning.

19 Oct, 2021 | 09:53h | UTC

China’s COVID vaccines have been crucial — now immunity is waning – Nature

Related:

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

 

Systematic Review: Restricting access to poisons is associated with decreases in suicide by poisoning without an equivalent shift toward other methods.

20 Oct, 2021 | 09:48h | UTC

Association Between Means Restriction of Poison and Method-Specific Suicide Rates: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 

BJS commission on surgery and perioperative care post-COVID-19.

19 Oct, 2021 | 09:52h | UTC

BJS commission on surgery and perioperative care post-COVID-19 – British Journal of Surgery

Related: Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.

 

Commentary on Twitter

 

Editorial: Preparing for “Disease X”.

19 Oct, 2021 | 09:54h | UTC

Preparing for “Disease X” – Science

 

Another observational study suggests Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants.

19 Oct, 2021 | 09:47h | UTC

Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD

Related: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study – Gastroenterology

 

Commentary on Twitter

 

Cluster RCT: An exercise intervention may improve academic achievement among children.

19 Oct, 2021 | 09:45h | UTC

Exercise Intervention for Academic Achievement Among Children: A Randomized Controlled Trial – Pediatrics

 

Commentary on Twitter

 

Guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery.

19 Oct, 2021 | 09:50h | UTC

S3 guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery – Journal of the German Society of Dermatology

 

Systematic Review: Calcium channel blockers versus other classes of drugs for hypertension – “there is moderate certainty evidence that diuretics reduce major cardiovascular events and congestive heart failure more than CCBs”.

19 Oct, 2021 | 08:56h | UTC

Summary: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

Original Study: Calcium channel blockers versus other classes of drugs for hypertension – Cochrane Library

 

Commentary on Twitter

 

Urolithiasis: ED presentations, evaluation, management, and disposition.

19 Oct, 2021 | 08:53h | UTC

Urolithiasis: ED Presentations, Evaluation, Management, and Disposition – emDocs

 

Podcast: Diagnosis and treatment of Celiac Disease.

19 Oct, 2021 | 08:54h | UTC

#300 Celiac Disease with Dr. Amy Oxentenko – The Curbsiders

 

Preoperative hypertension: perioperative implications and management.

19 Oct, 2021 | 08:51h | UTC

Preoperative hypertension: perioperative implications and management – BJA Education

 

Bioethics | The Reluctant Patient and the Insistent Doctor.

19 Oct, 2021 | 08:50h | UTC

The Reluctant Patient and the Insistent Doctor – The American Journal of Medicine

 

Review: Wilms Tumor.

19 Oct, 2021 | 08:44h | UTC

Wilms tumour – Nature Reviews Disease Primers (free for a limited period)

Infographic: Wilms tumour

 

Commentary on Twitter

 

Opinion | Multi-cancer screening tests: communicating about risks should be prioritized.

19 Oct, 2021 | 08:49h | UTC

Multi-cancer screening tests: communicating about risks should be prioritized. – The American Journal of Medicine

 

RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.

17 Oct, 2021 | 21:35h | UTC

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ

Commentary: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital

Related studies (some conflicting results)

RCT: Therapeutic-dose heparin superior to standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.

Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.

M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity.

RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.

RCT: In critically ill patients with Covid-19, therapeutic anticoagulation with heparin did not result in improved outcomes compared to usual-care pharmacologic thromboprophylaxis.

RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

 

Commentary on Twitter

 

Review: Stroke prevention after cryptogenic stroke.

19 Oct, 2021 | 08:46h | UTC

Stroke Prevention After Cryptogenic Stroke – Current Cardiology Reports

Related:

2 recent meta-analysis highlight the benefits of short term (30 days) dual antiplatelet therapy with aspirin + clopidogrel in patients within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke.

Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke – The BMJ

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management – National Institute for Health and Care Excellence

Canadian Stroke Best Practice Recommendations for Acute Stroke Management

 

M-A: Risk factors for invasive candida infection in critically ill patients – The risk factors associated with the highest risk for ICI were broad spectrum antibiotics (OR 5.6), blood transfusion (OR 4.9), Candida colonization (OR 4.7), central venous catheter (OR 4.7) and total parenteral nutrition (OR 4.6).

19 Oct, 2021 | 08:47h | UTC

Risk factors for invasive candida infection in critically ill patients – a systematic review and meta-analysis – Chest

 

J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

17 Oct, 2021 | 21:32h | UTC

News release: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Commentaries:

FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press

The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN

FDA advisers recommend J&J Covid-19 vaccine boosters, talk mix and match boosters – CNN

Related: [Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

 

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

17 Oct, 2021 | 21:29h | UTC

Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – medRxiv

Related:

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

 

Commentary on Twitter

 

Review: SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19.

17 Oct, 2021 | 21:30h | UTC

SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review – Clinical Infectious Diseases

Related: Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19.

 

Commentary from the author on Twitter (thread – click for more)

 

Management of Diabetes Mellitus in patients with CKD: Core Curriculum 2022.

17 Oct, 2021 | 21:23h | UTC

Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022 – American Journal of Kidney Diseases

 

What can masks do? Part 2: What makes for a good mask study — and why most fail.

17 Oct, 2021 | 21:25h | UTC

COMMENTARY: What can masks do? Part 2: What makes for a good mask study — and why most fail – CIDRAP

See also: COMMENTARY: What can masks do? Part 1: The science behind COVID-19 protection – CIDRAP

 

Guidelines for the surgical management of ulcerative colitis.

17 Oct, 2021 | 21:21h | UTC

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis – Diseases of the Colon & Rectum

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.